Ratings Amgen Inc. Buenos Aires S.E.

Equities

AMGN

ARDEUT110665

End-of-day quote Buenos Aires S.E. Other stock markets 03:30:00 06/06/2024 am IST			5-day change	1st Jan Change
13,256 ^ARS	-1.16%		+8.56%	+42.03%

06/06	Transcript : Amgen Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-06-2024 09:00 AM
05/06	Amgen Says Phase 3 Trial of Potential Autoimmune Disease Treatment Meets Endpoints	MT

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Over the past twelve months, analysts' opinions have been strongly revised upwards.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
With an expected P/E ratio at 38.54 and 24.77 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
Based on current prices, the company has particularly high valuation levels.
The company appears highly valued given the size of its balance sheet.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
AMGEN INC.	+42.03%	16TCr	-
ELI LILLY AND COMPANY	+43.64%	75TCr	C+
NOVO NORDISK A/S	+39.42%	61TCr	B
JOHNSON & JOHNSON	-6.58%	35TCr	C+
MERCK & CO., INC.	+19.72%	33TCr	B-
ABBVIE INC.	+8.78%	29TCr	C+
NOVARTIS AG	+11.92%	22TCr	B-
ROCHE HOLDING AG	-2.62%	21TCr	A+
PFIZER, INC.	+0.03%	17TCr	C+
SANOFI	+1.39%	12TCr	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes